Premenstrual dysphoric disorder (PMDD) is a severe, cyclic mood disorder characterized by affective, cognitive and somatic symptoms arising in the luteal phase and remitting shortly after onset of menstruation. Unlike typical premenstrual syndrome (PMS), PMDD involves marked impairment in functioning.

Diagnostic Framework

According to DSM-type criteria, PMDD requires:

• At least five symptoms in the final week before menses, improving within a few days after onset, and minimal in the week post-menses.
• At least one prominent affective symptom: mood lability, marked irritability/anger, depressed mood or anxiety/tension.
• Clinically significant distress or interference with work, school, social activities or relationships.

Prospective daily ratings across ≥2 cycles are recommended to confirm the temporal pattern.

Pathophysiology: Sensitivity, Not Hormone Excess

Hormone levels in PMDD are often within normal ranges. Current models focus on abnormal sensitivity to normal ovarian steroid fluctuations, rather than absolute excess.

Key elements:

• Estradiol and progesterone modulate neurotransmitter systems (serotonin, GABA, glutamate). In susceptible individuals, these shifts may produce exaggerated mood responses.
• Allopregnanolone, a neuroactive metabolite of progesterone, acts on GABAᴀ receptors; altered sensitivity to allopregnanolone has been implicated in PMDD, with paradoxical anxiogenic/dysphoric effects.
• Genetic and epigenetic factors likely influence receptor expression and intracellular signalling in these pathways.

Brain Circuits

Neuroimaging studies suggest altered reactivity in:

• Amygdala and limbic regions, associated with emotional salience and threat detection.
• Prefrontal regulatory networks, involved in top-down control of affect and impulses.
• Default mode and salience networks, potentially contributing to rumination and heightened interoceptive focus in the luteal phase.

These changes interact with psychosocial factors (stress, trauma history, interpersonal context) to shape clinical presentation.

Treatment Principles

• Serotonergic antidepressants (e.g. SSRIs) are evidence-based for PMDD and can be used continuously or restricted to the luteal phase under medical supervision.
• Hormonal interventions (combined oral contraceptives with specific progestins, ovulation suppression strategies) may reduce cyclic hormonal fluctuations.
• Psychotherapeutic approaches (CBT, skills for emotion regulation, interpersonal work) support coping and relationship stability.

Lifestyle measures (sleep hygiene, movement, stress reduction) act as non-pharmacological modulators of brain systems engaged in PMDD.

PMDD illustrates how normal endocrine rhythms can produce disabling symptoms in a nervous system with altered sensitivity. Recognizing it as a legitimate disorder supports timely diagnosis, destigmatization and multimodal treatment.